CMS’s 2026 Interoperability Standards and Prior Authorization for Drugs proposed rule (CMS-0062-P) has a public comment deadline of June 15, 2026 — three days from publication of this issue. The rule extends the 2024 electronic prior authorization framework beyond nondrug items and services to drugs covered under both medical and pharmacy benefits, introducing shorter decision timelines, electronic PA requirements, standardized data exchange, and more specific denial explanations. If finalized, most requirements would take effect October 1, 2027.
Submit comments on CMS-0062-P at regulations.gov by June 15, 2026. Specialty practices prescribing biologics, chemotherapy, and specialty drugs under Medicare or Medicaid have the most at stake. Comments submitted by individual practices carry significant weight in CMS’s rulemaking record.
The proposed rule applies to all HIPAA-covered entities — health care providers, health plans, and clearinghouses — that electronically exchange prior authorization requests and decisions for drugs. Key proposals include:
The CY 2026 Medicare Physician Fee Schedule included a permanent 2.5% efficiency adjustment applied to approximately 7,700 procedural and diagnostic wRVU values. Combined with the 3.26% conversion factor increase, net reimbursement effects are mixed: primary care and E&M-heavy specialties benefited modestly, while procedural specialties face real revenue compression. Cardiology, orthopedics, radiology, surgery, and pathology are most impacted.
Massachusetts Governor Healey’s final regulations eliminating prior authorization for routine and essential health care took effect June 5, 2026 — making Massachusetts the most aggressive state PA reformer in the nation. Practices billing Massachusetts commercial payers must update intake workflows immediately to avoid generating unnecessary PA requests for newly exempted service categories.
Insurers must respond within 24 hours for urgently needed care, provide specific denial explanations, and honor continuity of care protections. Any payer that continues requiring PA for eliminated service categories can be reported to the Massachusetts Division of Insurance.
Virginia’s new PA law — establishing minimum decision durations and AI oversight requirements for algorithmic PA decision tools — also took effect in June 2026. Virginia payers using AI-driven PA systems must now provide transparency about the algorithms, allow human override, and meet documentation standards. The law represents the leading edge of a national regulatory movement around AI transparency in insurance operations.
AHIP and the Blue Cross Blue Shield Association jointly report an 11% reduction in prior authorizations since the 2025 voluntary industry commitments. The Massachusetts reform and Virginia AI law demonstrate that voluntary progress is being supplemented by binding state regulation — and CMS’s proposed drug PA rule would add federal mandate pressure on top of state actions.
The Healthcare Financial Management Association’s 2026 Annual Conference (June 7–10, National Harbor, Maryland) declared AI readiness and denial prevention the defining themes of healthcare finance for the next 36 months. The conference drew healthcare CFOs, RCM directors, and technology leaders to debate how quickly AI can transform the cost structure of revenue cycle operations.
FinThrive showcased FinThrive Fusion — an AI-powered platform integrating advanced analytics, automation, and expanded AI capabilities across the revenue lifecycle. Conference sessions demonstrated denial prevention performance improvements and revenue integrity gains from the platform’s integrated approach to pre-submission claim scrubbing and post-denial management.
UiPath announced new agentic AI solutions for the healthcare industry targeting three key RCM workflows: claim denial prevention and resolution, prior authorization automation, and medical records summarization. UiPath is partnering with Genzeon — one of only six technology vendors selected by CMS for the Wasteful and Inappropriate Service Reduction (WISeR) Model — to deliver the PA automation solution, adding regulatory legitimacy to the deployment.
Black Book Research released its 2026 Vendor-Agnostic Revenue Cycle Management Qualitative KPI Results on June 3 ahead of HFMA, providing a governance standard for evaluating autonomous workflows, agentic AI, coding automation, and AI-assisted recommendation systems. The framework evaluates whether these tools are reliable, explainable, auditable, and operationally accountable — the four dimensions now expected by CFOs and compliance teams.
Despite the technology focus, conference attendees emphasized that the top investment priority must remain people. The best RCM AI deployments are those that reskill and upskill existing staff — elevating coders to denial management, revenue integrity, and physician education roles rather than creating workforce reductions. Automation without workforce development creates institutional knowledge gaps that compound over time.
The CPT 2026 code set — with 288 new codes, 84 deletions, and 46 revisions — contains the most significant overhaul to radiation oncology billing in more than a decade. Practices providing radiation therapy that have not yet updated their charge masters should treat this as an emergency coding audit.
IMRT codes 77385 and 77386 are deleted effective January 1, 2026. Any radiation oncology practice still billing these codes will receive automatic CO-4 denials. Update all charge master templates, order sets, and encounter forms immediately.
The simple (77402), intermediate (77407), and complex (77412) radiation treatment delivery codes are replaced by Level 1, Level 2, and Level 3 codes with revised clinical descriptors that better reflect current treatment planning and delivery technology. Practices must map existing protocols to the new level structure before billing.
Four new Principal Illness Navigation (PIN) codes — G0023, G0024, G0140, and G0146 — reimburse individualized navigation support to help patients identify appropriate practitioners and manage complex chronic conditions. These codes are directly applicable to primary care, oncology care coordination, and complex chronic disease management practices.
The industry has converged on a set of measurable 2026 benchmarks that separate high-performing practices from those silently leaking revenue. These metrics — now validated across thousands of practices — provide a common language for revenue velocity performance management.
Every 1% below clean claims benchmark removes approximately 0.3–0.5 days from the average AR cycle — because rework adds 30–60 days to a touched claim’s collection cycle. A practice running at 93% clean claims versus 98% is carrying an unnecessary 2–3 extra days in AR as a structural overhead. At $10M annual revenue, that translates to approximately $55,000–$82,000 in delayed cash.
| Payer Type | Days to Payment | Key Variable |
|---|---|---|
| Medicare FFS | 14 days | Prompt-pay rule; clean claim required |
| Commercial (UHC, Aetna, Cigna, BCBS) | 15–22 days | Payer-specific contract terms |
| Medicaid (TX) | 21–28 days | State system performance |
| Medicaid (NY) | 25–35 days | State system performance |
| Medicaid (CA Medi-Cal) | 30–45 days | Volume-intensive state system |
| Aging Bucket | Danger Zone | Target | Best in Class |
|---|---|---|---|
| 0–30 Days | < 55% | 65–75% | > 75% |
| 31–60 Days | > 25% | 12–18% | < 12% |
| 61–90 Days | > 15% | 6–10% | < 6% |
| 91+ Days | > 20% | < 15% | < 10% |
Run your AR aging report this week. If your 91+ bucket exceeds 15%, initiate a targeted recovery sweep on accounts in the 60–90 day range before they age past the high-recovery threshold. Real-time denial dashboards — not monthly reports — are now the standard at best-in-class practices.
Agentic AI for Revenue Cycle Management has emerged as the fastest-growing application within healthcare AI, holding a 20.8% market share in the broader agentic AI healthcare sector in 2026. The RCM AI market is projected to grow from $1.83 billion in 2026 to $19.71 billion by 2034, driven by the shift from rule-based RPA toward AI agents that can interpret complex payer contracts, medical necessity requirements, and clinical documentation without human review.
| Capability | Legacy RPA | Agentic AI |
|---|---|---|
| Handles rule changes | Fails; requires reprogramming | Adapts from payer behavior data |
| Payer contract interpretation | Cannot; rules only | NLP-based contract analysis |
| Exception handling | Routes to human queue | Resolves autonomously or escalates intelligently |
| Appeals letter generation | Template-only | Generative AI drafts payer-specific arguments |
| PA initiation | Form-fill bots only | End-to-end PA workflow including clinical justification |
The leading agentic AI and AI-native RCM vendors featured in Black Book Research’s 2026 framework and HFMA discussions include: FinThrive, Waystar, Experian Health, Innovaccer, MedEvolve, SmarterDx (SmarterDenials), Rivet, UiPath/Genzeon, Optum, CombineHealth, and Kyron Medical.
Practices that switched to AI-native RCM partners are seeing denial rates drop to ~5.7% — versus 12–22% in manual environments. At a practice generating $5M in annual revenue, moving from 15% to 5.7% denial rates represents approximately $465,000 in recoverable annual revenue — either recovered faster or prevented from being denied at all.
Three distinct compliance obligations converge this week — one with a hard three-day countdown, one reshaping your patient payer mix for 2027, and one that could trigger civil monetary penalties if hospital machine-readable files are incomplete.
The proposed rule (CMS-0062-P) extending electronic PA requirements to drugs closes for public comment on June 15, 2026. Comments are accepted at regulations.gov by referencing file code CMS-0062-P. Specialty practices prescribing biologics, chemotherapy, and specialty drugs under Medicare Advantage or Medicaid have the most at stake. Key areas for practitioner comment include whether the proposed 72-hour standard decision timeline is operationally realistic for complex oncology or rheumatology PA requests, and whether smaller practices have sufficient IT infrastructure to support FHIR-based drug PA exchange by the proposed October 2027 deadline.
The CMS interim final rule (CMS-2454-IFC, effective June 1, 2026) requires states to implement 80 hours/month work requirements for non-elderly, non-pregnant Medicaid adults by January 1, 2027. CMS projects:
Practices with significant Medicaid volume must model payer mix exposure, develop financial counseling workflows for disenrollees, and review charity care policy applicability for patients transitioning to self-pay or marketplace coverage.
Effective January 1, 2026, hospitals must calculate and encode the 10th percentile, median, and 90th percentile allowed amounts for each item or service in machine-readable files — along with the total number of remittances used to calculate them. CMS enforcement began April 1, 2026. Non-compliant hospitals face civil monetary penalties up to $2 million per year for large facilities and $300 per day for facilities up to 30 beds.
Submit comments on CMS-0062-P at regulations.gov by June 15. Review your Medicaid patient panel now to model 2027 coverage loss exposure. Hospitals must verify price transparency machine-readable files include 10th/median/90th percentile data or risk penalty accumulation since April 1.
Independent practices are facing a defining pressure test in mid-2026. The combination of Medicaid community engagement rules, specialty-specific wRVU cuts, rising denial rates, and the AI deployment gap is creating a “slow bleed” scenario for practices that aren’t actively managing each variable.
With CMS estimating 2.3 million Medicaid disenrollments in 2027, practices in states with high Medicaid participation face immediate payer mix modeling needs. A practice with 20% Medicaid volume and typical commercial conversion rates of 40% (patients gaining marketplace coverage) faces a 12% effective patient revenue risk that compounds year over year as state-level disenrollment ramps up. Solo and small-group practices without financial cushion are most exposed.
| KPI | Danger Zone | Target | Best in Class |
|---|---|---|---|
| Days in AR | > 50 days | 30–40 days | < 25 days |
| Clean Claims Rate | < 92% | ≥ 95% | 98–99%+ |
| Denial Rate (first submission) | > 15% | < 8% | < 5.7% |
| AR Aged 91+ Days | > 20% | < 15% | < 10% |
| Net Collections Rate | < 92% | 95–97% | > 97% |
| AI/Automation Workflows Deployed | 0 workflows | 2–3 workflows | 5+ workflows |
Independent practices must act on three priorities this week: (1) Comment on CMS Drug PA rule by June 15, (2) if billing Massachusetts commercial payers, strip PA steps from eliminated service categories immediately, and (3) begin modeling Medicaid exposure for 2027 disenrollment scenarios before state plans are locked.
Massachusetts PA reform directly benefits primary care practices — eliminating prior authorization for primary care visits, chronic condition medications (diabetes, asthma, heart disease), and post-acute weekend/holiday services. Practices billing Massachusetts commercial payers should immediately update intake workflows to remove PA steps for these categories. Additionally, the 4 new Principal Illness Navigation (PIN) codes — G0023, G0024, G0140, and G0146 — create new billable encounters for individualized chronic care navigation. Verify these codes are active in your charge master and that care coordinators are documenting navigation services appropriately. These codes are explicitly designed for primary care practices managing complex chronic patients.
Two simultaneous hits for cardiology billing in 2026. First, CPT 33340 (Percutaneous Left Atrial Appendage Occlusion/Watchman) wRVU declined 26.8% from 14.00 to 10.25 — the most significant cardiology reimbursement cut in this fee schedule cycle. Practices performing Watchman implants should model revenue-per-procedure impact and initiate contract renegotiations with commercial payers that use Medicare-relative fee schedules. Second, the entire PCI code family was revised; a single lesion spanning multiple segments no longer qualifies as multiple reportable lesions — practices that have been billing PCI multiplicity based on anatomical segment traversal face audit exposure and should conduct a prospective claims audit.
CMS’s strict 2026 interpretation of global surgical packages narrows what is separately billable during pre- and post-operative periods. Combined with the 2.5% wRVU efficiency adjustment hitting surgical codes, orthopedic practices should audit global period documentation and confirm that modifier-57 usage is clinically defensible. Annual revenue exposure from global package misinterpretation can exceed $40,000 per surgeon in a 3-physician orthopedic group. Conduct a global period compliance review before the next CMS audit cycle.
Radiation therapy billing undergoes its most significant change since 2013. The simple/intermediate/complex delivery codes (77402, 77407, 77412) are replaced by Level 1/2/3 codes with revised clinical descriptors. IMRT codes 77385 and 77386 are deleted — any charge master, order set, or EHR template using these codes will generate CO-4 denials. Also: four new PIN codes (G0023, G0024, G0140, G0146) support oncology patient navigation reimbursement — oncology care coordinators who guide patients through treatment planning are now billable under these codes. Verify ASCO guidance on code applicability.
NCCI modifier audit remains a top priority for neurology practices in 2026. Incorrect modifier 26/TC usage is the leading source of CO-4 denials for neurophysiologic monitoring, EEG, and EMG services. Practices should run a prospective claims audit against the 2026 NCCI tables before each billing cycle. The Virginia PA AI oversight law affecting behavioral neurological assessments requires attention from Virginia-based neurology practices billing payers that use algorithmic PA decision tools.
Virginia’s new PA law — requiring transparency and human review override capabilities for algorithmic PA decisions — is effective in June 2026 and directly affects behavioral health service authorizations. Virginia mental health practices should verify that their commercial payers are complying with the new AI oversight requirements. Nationally, telehealth behavioral health coverage extensions under the CY 2026 PFS are now permanent — a meaningful billing stability win for independent mental health practices that built telehealth volume during 2020–2025 and need long-term reimbursement certainty.